New Stock First Day | MyWay Biotechnology-B (02493) First Listed, Opening at 2.39% Higher in the Morning Session, Leading the Global clinical progress of the flagship product 9MW2821

Maiwei Biological-B (02493) made its debut on the stock market. The announcement shows that the price per share is HK$27.64, with a total of 471.302 million shares issued. Each lot consists of 200 shares, with a net amount raised of approximately HK$1.189 billion. As of the time of writing, the stock has risen by 2.39%, trading at HK$28.3 with a trading volume of HK$381.87 million. Public information shows that Maiwei Biological (02493) is an innovative pharmaceutical company with end-to-end capabilities from drug discovery to commercial sales. Its research is focused on the hot areas of ADC (antibody-drug conjugates) and TCE (T-cell engaging antibodies) in the field of oncology. The company's flagship product 9MW2821 is leading globally in clinical progress, with multiple indications entering Phase III clinical trials. At the same time, the company has successfully commercialized four products, demonstrating its ability to realize the full chain from research and development to sales. It is worth noting that the Shanghai and Shenzhen Stock Exchanges have announced that Maiwei Biological-B will not be subject to the price stabilization period mechanism on the Hong Kong Stock Exchange. Additionally, after the A shares have been listed for 10 trading days, Maiwei Biological-B will be included in the list of securities eligible for trading through the Stock Connect program, effective from April 28. In January 2022, the company's A shares were listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, and in March 2024, they were included in the FTSE Global Equity Index.